Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 3, 2002, Pages 577-586

  Elizalde, J I ^a   Pique J M ^a   Moreno, V ^b   Morillas, J D ^c,g   Elizalde, I ^a   Bujanda, L ^d   De Argila, C M ^e   Cosme, A ^f   Castiella, A ^a   Ros, E ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Hospital de San Eloy   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f Hospital Nuestra Senora de Aranzazu   (Spain)

^g Universidad Pública de Navarra   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CHOLESTEROL; CLARITHROMYCIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; OMEPRAZOLE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOSCOPY; ERADICATION THERAPY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIFESTYLE; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AMOXICILLIN; BIOLOGICAL MARKERS; CLARITHROMYCIN; FEMALE; FIBRINOGEN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; OMEPRAZOLE; RISK FACTORS;

EID: 0036191539     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01202.x     Document Type: Article

References (42)

1. Atherosclerosis. An inflammatory disease
2. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association
3. Plaque disruption and thrombosis: Potential role of inflammation and infection
4. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis
5. Chronic Chlamydia pnenmoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study
6. Relation of Helicobacter pylori infection and coronary heart disease
7. Association of virulent Helicobacter pylori strains with ischemic heart disease
8. Cytomegalovirus/herpesvirus and carotid atherosclerosis: The ARIC study
9. Helicobacter pylori seropositivity in myocardial infarction
10. Helicobacter pylori infection and mortality from ischemic heart disease: Negative result from a large, prospective study
11. Helicobacter pylori seropositivity in subjects with acute myocardial infarction
12. Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the Caerphilly Prospective Heart Disease Study
13. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis
14. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis
15. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms
16. Infection and inflammation-induced proatherogenic changes of lipoproteins
17. Could Helicobacter pylori increase the risk of coronary heart disease by modifying serum lipid concentrations?
18. Association of Helicobacter pylori infection with elevated serum lipids
19. Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and degrees of coronary artery disease
20. Risk factors for coronary heart disease and infection with Helicobacter pylori: Meta-analysis of 18 studies
21. Helicobacter pylori CagA seropositivity does not influence inflammatory parameters, lipid concentrations and hemostatic factors in healthy individuals
22. Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients
23. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or Cytomegalovirus is associated with an atherogenic, modified lipid profile
24. Do triglycerides provide meaningful information about heart disease risk?
25. Perfil lipidico de la población española: Estudio DRECE (Dieta y Riesgo de Enfermedad Cardiovascular en España)
26. Urea breath tests in the management of Helicobacter pylori infection
27. The Eating Pattern Assessment tool: A simple instrument for assessing dietary fat and cholesterol intake
28. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: Executive summary
29. Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents
30. Reduced cholesterol is associated with recent minor illness: The CARDIA study
31. Role of cytokines in inducing hyperlipidemia
32. How does Helicobacter pylori cause mucosal damage? The inflammatory response
33. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
34. Improvement in lipid and haemostasis patterns after Helicobacter pylori eradication in type 1 diabetic patients
35. Successful eradication of Helicobacter pylori as determined by 13C-urea breath test does not alter fibrinogen and acute phase response markers
36. Helicobacter pylori infection. The Spanish consensus report
37. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: A randomised controlled trial
38. Treatment for eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference
39. New perspectives on the management of low levels of high density lipoprotein cholesterol
40. Anti-inflammatory activity of macrolide antibiotics
41. Treatment of Helicobacter pylori and Chlamydia pneumoniae infection decreases fibrinogen plasma level in patients with ischemic heart disease
42. Decrease of plasma fibrinogen after eradication of Helicobacter pylori infection in patients with ischaemic heart disease